Abstract
Age is a major risk factor for solid cancers, hitherto conventionally viewed in the context of the cell biology of carcinogenesis. However, if cancers are immunogenic, the immune system could protect against tumorigenesis (“immunosurveillance”), and vaccination or other immunomodulatory treatments should be therapeutically beneficial, as has been recently dramatically documented in a fraction of patients with certain tumors responding to immune checkpoint blockade. This begs the question that if immunity decreases with age (“immunosenescence”), this may contribute to increased cancer disease in the elderly and a lower likelihood of clinical benefit from immunotherapy. This brief review weighs up the evidence for and against a negative impact of immunosenescence on cancer control.
Similar content being viewed by others
References
Bailur JK, Derhovanessian E, Gueckel B, Pawelec G (2015) Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients. J Immunother Cancer 3:45. doi:10.1186/s40425-015-0090-0
Baldwin RW (1955) Immunity to methylcholanthrene-induced tumours in inbred rats following atrophy and regression of the implanted tumours. Br J Cancer 9(4):652–657
Burnet M (1973) Aging and immunological surveillance. Triangle 12(4):159–162
Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L et al (2014) Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res 33:30. doi:10.1186/1756-9966-33-30
Chiu YL, Lin CH, Sung BY, Chuang YF, Schneck JP, Kern F et al (2016) Cytotoxic polyfunctionality maturation of cytomegalovirus-pp65-specific CD4+ and CD8+ T-cell responses in older adults positively correlates with response size. Sci Rep 6:19227. doi:10.1038/srep19227
Derhovanessian E, Maier AB, Beck R, Jahn G, Hahnel K, Slagboom PE et al (2010) Hallmark features of immunosenescence are absent in familial longevity. J Immunol 185(8):4618–4624. doi:10.4049/jimmunol.1001629
Di Benedetto S, Derhovanessian E, Steinhagen-Thiessen E, Goldeck D, Muller L, Pawelec G (2015) Impact of age, sex and CMV-infection on peripheral T cell phenotypes: results from the Berlin BASE-II Study. Biogerontology 16(5):631–643. doi:10.1007/s10522-015-9563-2
Effros RB, Pawelec G (1997) Replicative senescence of T cells: does the Hayflick limit lead to immune exhaustion? Immunol Today 18(9):450–454
Fulop T, Dupuis G, Baehl S, Le Page A, Bourgade K, Frost E et al (2016) From inflamm-aging to immune-paralysis: a slippery slope during aging for immune-adaptation. Biogerontology 17(1):147–157. doi:10.1007/s10522-015-9615-7
Helissey C, Vicier C, Champiat S (2016) The development of immunotherapy in older adults: new treatments, new toxicities? J Geriatr Oncol 7(5):325–333. doi:10.1016/j.jgo.2016.05.007
Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18(1):31–41. doi:10.1016/S1470-2045(16)30624-6
Hurez V, Daniel BJ, Sun L, Liu AJ, Ludwig SM, Kious MJ et al (2012) Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res 72(8):2089–2099. doi:10.1158/0008-5472
Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z et al (2013) Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res 1(4):235–244. doi:10.1158/2326-6066.CIR-13-0068
Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ et al (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450(7171):903–907. doi:10.1038/nature06309
Ledford H (2011) Melanoma drug wins US approval. Nature 471(7340):561. doi:10.1038/471561a
Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P et al (2016) baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 22(12):2908–2918. doi:10.1158/1078-0432.CCR-15-2412
McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD et al (2014) Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 40(9):1056–1064. doi:10.1016/j.ctrv.2014.06.012
Pawelec G (2012) Hallmarks of human “immunosenescence”: adaptation or dysregulation? Immun Ageing 9(1):15. doi:10.1186/1742-4933-9-15
Pawelec G (2014) Immunosenenescence: role of cytomegalovirus. Exp Gerontol 54:1–5. doi:10.1016/j.exger.2013.11.010
Pawelec G, Koch S, Griesemann H, Rehbein A, Hahnel K, Gouttefangeas C (2006) Immunosenescence, suppression and tumour progression. Cancer Immunol Immunother 55(8):981–986. doi:10.1007/s00262-005-0109-3
Pawelec G, Lustgarten J, Ruby C, Gravekamp C (2009) Impact of aging on cancer immunity and immunotherapy. Cancer Immunol Immunother 58(12):1907–1908
Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K (1981) Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59(6):895–900
Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN et al (2004) Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 27(6):478–479
Schreiber K, Arina A, Engels B, Spiotto MT, Sidney J, Sette A et al (2012) Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res 18(9):2526–2533. doi:10.1158/1078-0432.CCR-12-0127
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030. doi:10.1200/JCO.2013.53.0105
Valmori D, Souleimanian NE, Hesdorffer CS, Old LJ, Ayyoub M (2005) Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals. Clin Immunol 117(2):161–167. doi:10.1016/j.clim.2005.07.004
Verschoor CP, Johnstone J, Millar J, Dorrington MG, Habibagahi M, Lelic A et al (2013) Blood CD33(+)HLA-DR(−) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol 93(4):633–637. doi:10.1189/jlb.0912461
Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E et al (2015) Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 35(Suppl):S185–S198. doi:10.1016/j.semcancer.2015.03.004
Ward JP, Gubin MM, Schreiber RD (2016) The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer. Adv Immunol 130:25–74. doi:10.1016/bs.ai.2016.01.001
Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM et al (2012) Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 30(15):1835–1841. doi:10.1200/JCO.2011.40.2271
Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM et al (2014) Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res 20(6):1601–1609. doi:10.1158/1078-0432.CCR-13-2508
Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K et al (2016) Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. doi:10.1158/1078-0432.CCR-16-0127
Acknowledgements
This study was supported by DFG PA 361-22/1.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pawelec, G. Immunosenescence and cancer. Biogerontology 18, 717–721 (2017). https://doi.org/10.1007/s10522-017-9682-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10522-017-9682-z